HEADER TRANSPORT PROTEIN 20-JUN-13 4LB9 TITLE X-RAY STUDY OF HUMAN SERUM ALBUMIN COMPLEXED WITH ETOPOSIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: SERUM ALBUMIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: UNP RESIDUES 25-609 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606 KEYWDS PLASMA PROTEIN, CANCER, ONCOLOGY DRUG COMPLEX, TRANSPORT PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR Z.WANG,J.X.HO,J.RUBLE,J.P.ROSE,D.C.CARTER REVDAT 3 19-FEB-14 4LB9 1 REMARK REVDAT 2 23-OCT-13 4LB9 1 JRNL REVDAT 1 24-JUL-13 4LB9 0 JRNL AUTH Z.M.WANG,J.X.HO,J.R.RUBLE,J.ROSE,F.RUKER,M.ELLENBURG, JRNL AUTH 2 R.MURPHY,J.CLICK,E.SOISTMAN,L.WILKERSON,D.C.CARTER JRNL TITL STRUCTURAL STUDIES OF SEVERAL CLINICALLY IMPORTANT ONCOLOGY JRNL TITL 2 DRUGS IN COMPLEX WITH HUMAN SERUM ALBUMIN. JRNL REF BIOCHIM.BIOPHYS.ACTA V.1830 5356 2013 JRNL REFN ISSN 0006-3002 JRNL PMID 23838380 JRNL DOI 10.1016/J.BBAGEN.2013.06.032 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH D.C.CARTER REMARK 1 TITL CRYSTALLOGRAPHIC SURVEY OF ALBUMIN DRUG INTERACTION AND REMARK 1 TITL 2 PRELIMINARY APPLICATIONS IN CANCER CHEMOTHERAPY REMARK 1 REF BURGERS MEDICINAL CHEMISTRY 437 2010 REMARK 1 REF 2 DRUG DESIGN AND DEVELOPMENT, REMARK 1 REF 3 7TH EDITION REMARK 1 PUBL JOHN WILEY & SONS REMARK 1 REFN REMARK 1 DOI 10.1002/0471266949 REMARK 1 REFERENCE 2 REMARK 1 AUTH D.C.CARTER,J.X.HO REMARK 1 TITL STRUCTURE OF SERUM ALBUMIN REMARK 1 REF ADV.PROTEIN CHEM. V. 45 153 1994 REMARK 1 REFN ISSN 0065-3233 REMARK 1 REFERENCE 3 REMARK 1 AUTH D.C.CARTER,B.CHANG,J.X.HO,K.KEELING,Z.KRISHNASAMI REMARK 1 TITL PRELIMINARY CRYSTALLOGRAPHIC STUDIES OF FOUR CRYSTAL FORMS REMARK 1 TITL 2 OF SERUM ALBUMIN. REMARK 1 REF EUR.J.BIOCHEM. V. 226 1049 1994 REMARK 1 REFN ISSN 0014-2956 REMARK 1 PMID 7813459 REMARK 1 REFERENCE 4 REMARK 1 AUTH X.M.HO,D.C.CARTER REMARK 1 TITL ERRATUM. ATOMIC STRUCTURE AND CHEMISTRY OF HUMAN SERUM REMARK 1 TITL 2 ALBUMIN REMARK 1 REF NATURE V. 364 362 1993 REMARK 1 REFN ISSN 0028-0836 REMARK 1 REFERENCE 5 REMARK 1 AUTH X.M.HE,D.C.CARTER REMARK 1 TITL ATOMIC STRUCTURE AND CHEMISTRY OF HUMAN SERUM ALBUMIN. REMARK 1 REF NATURE V. 358 209 1992 REMARK 1 REFN ISSN 0028-0836 REMARK 1 PMID 1630489 REMARK 1 DOI 10.1038/358209A0 REMARK 1 REFERENCE 6 REMARK 1 AUTH D.C.CARTER,X.M.HO REMARK 1 TITL STRUCTURE OF HUMAN SERUM ALBUMIN REMARK 1 REF SCIENCE V. 249 302 1990 REMARK 1 REFN ISSN 0036-8075 REMARK 1 REFERENCE 7 REMARK 1 AUTH D.C.CARTER,X.M.HE,S.H.MUNSON,P.D.TWIGG,K.M.GERNERT, REMARK 1 AUTH 2 M.B.BROOM,T.Y.MILLER REMARK 1 TITL THREE-DIMENSIONAL STRUCTURE OF HUMAN SERUM ALBUMIN. REMARK 1 REF SCIENCE V. 244 1195 1989 REMARK 1 REFN ISSN 0036-8075 REMARK 1 PMID 2727704 REMARK 2 REMARK 2 RESOLUTION. 2.70 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: 1.8.2_1309) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VICENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE- REMARK 3 : KUNSTLEVE,LI-WEI HUNG,ROBERT IMMORMINO, REMARK 3 : TOM IOERGER,AIRLIE MCCOY,ERIK MCKEE,NIGEL REMARK 3 : MORIARTY,REETAL PAI,RANDY READ,JANE REMARK 3 : RICHARDSON,DAVID RICHARDSON,TOD ROMO,JIM REMARK 3 : SACCHETTINI,NICHOLAS SAUTER,JACOB SMITH, REMARK 3 : LAURENT STORONI,TOM TERWILLIGER,PETER REMARK 3 : ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.70 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 25.68 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 86.6 REMARK 3 NUMBER OF REFLECTIONS : 15540 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.197 REMARK 3 R VALUE (WORKING SET) : 0.195 REMARK 3 FREE R VALUE : 0.249 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.920 REMARK 3 FREE R VALUE TEST SET COUNT : 764 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 25.6797 - 4.6098 0.90 3181 157 0.1785 0.2085 REMARK 3 2 4.6098 - 3.6623 0.92 3142 166 0.1763 0.2304 REMARK 3 3 3.6623 - 3.2004 0.86 2877 148 0.2008 0.2632 REMARK 3 4 3.2004 - 2.9082 0.83 2801 148 0.2509 0.3468 REMARK 3 5 2.9082 - 2.7000 0.82 2775 145 0.2464 0.3377 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.410 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 26.860 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 33.18 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.005 4851 REMARK 3 ANGLE : 1.024 6508 REMARK 3 CHIRALITY : 0.072 718 REMARK 3 PLANARITY : 0.004 838 REMARK 3 DIHEDRAL : 16.992 1855 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4LB9 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 02-JUL-13. REMARK 100 THE RCSB ID CODE IS RCSB080413. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-JAN-03 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU300 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : CONFOCAL OPTICS REMARK 200 OPTICS : CONFOCAL OPTICS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15546 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.700 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 86.6 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.06800 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 12.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.70 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.80 REMARK 200 COMPLETENESS FOR SHELL (%) : 83.5 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.52200 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MERLOT REMARK 200 SOFTWARE USED: MERLOT REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 48.89 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.41 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PEG 3350, POTASSIUM PHOSPHATE, REMARK 280 CRYSTALS OF THE COMPLEXES WERE OBTAINED BY STANDARD VAPOR REMARK 280 EQUILIBRATION METHODS WITH CONDITIONS OPTIMIZED BY SCREENS REMARK 280 VARYING PROTEIN CONCENTRATION, PH, DRUG MOLAR RATIOS, CENTERED ON REMARK 280 THE ORIGINAL CRYSTALLIZATION HIT USING PROTOCOLS DESCRIBED REMARK 280 PREVIOUSLY FOR THE MONOCLINIC [CARTER, ET AL., EUR. J. REMARK 280 BIOCHEMISTRY (1994) 226: 1049-1052] AND TRICLINIC [SUGO, ET AL., REMARK 280 PROTEIN ENG (1999) 12: 439-446] CRYSTAL FORMS., PH 7.5, VAPOR REMARK 280 DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 86.27150 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 19.33850 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 86.27150 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 19.33850 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A 709 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ASP A 1 REMARK 465 LEU A 585 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 723 O HOH A 739 1.91 REMARK 500 O HOH A 719 O HOH A 738 2.06 REMARK 500 O CYS A 369 O HOH A 716 2.09 REMARK 500 OE1 GLU A 294 O HOH A 734 2.11 REMARK 500 OE1 GLU A 167 O HOH A 740 2.15 REMARK 500 O PHE A 206 O HOH A 741 2.16 REMARK 500 NZ LYS A 519 O HOH A 762 2.18 REMARK 500 OE1 GLN A 170 O HOH A 721 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 HIS A 3 -34.89 68.69 REMARK 500 ALA A 59 -148.05 -72.76 REMARK 500 GLU A 60 -89.72 -69.13 REMARK 500 ASN A 61 52.92 -109.37 REMARK 500 ALA A 78 -78.46 -47.88 REMARK 500 THR A 83 -48.34 -141.41 REMARK 500 ASN A 109 68.46 -111.68 REMARK 500 PRO A 113 -115.14 -64.39 REMARK 500 ARG A 114 115.58 -171.51 REMARK 500 ASN A 130 87.77 178.16 REMARK 500 TYR A 148 -28.98 71.33 REMARK 500 PHE A 223 59.47 -118.75 REMARK 500 ILE A 271 -64.25 -133.28 REMARK 500 CYS A 279 0.32 -68.75 REMARK 500 ASP A 301 102.20 60.66 REMARK 500 VAL A 310 -50.21 -135.46 REMARK 500 GLU A 321 -89.80 -56.59 REMARK 500 ASP A 365 77.90 -150.86 REMARK 500 GLU A 442 -70.65 -0.61 REMARK 500 THR A 467 85.02 -153.21 REMARK 500 VAL A 469 -1.36 -143.69 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A 601 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A 602 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A 603 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A 604 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EVP A 605 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4L8U RELATED DB: PDB REMARK 900 RELATED ID: 4L9K RELATED DB: PDB REMARK 900 RELATED ID: 4L9Q RELATED DB: PDB REMARK 900 RELATED ID: 4LA0 RELATED DB: PDB REMARK 900 RELATED ID: 4LB2 RELATED DB: PDB DBREF 4LB9 A 1 585 UNP P02768 ALBU_HUMAN 25 609 SEQRES 1 A 585 ASP ALA HIS LYS SER GLU VAL ALA HIS ARG PHE LYS ASP SEQRES 2 A 585 LEU GLY GLU GLU ASN PHE LYS ALA LEU VAL LEU ILE ALA SEQRES 3 A 585 PHE ALA GLN TYR LEU GLN GLN CYS PRO PHE GLU ASP HIS SEQRES 4 A 585 VAL LYS LEU VAL ASN GLU VAL THR GLU PHE ALA LYS THR SEQRES 5 A 585 CYS VAL ALA ASP GLU SER ALA GLU ASN CYS ASP LYS SER SEQRES 6 A 585 LEU HIS THR LEU PHE GLY ASP LYS LEU CYS THR VAL ALA SEQRES 7 A 585 THR LEU ARG GLU THR TYR GLY GLU MET ALA ASP CYS CYS SEQRES 8 A 585 ALA LYS GLN GLU PRO GLU ARG ASN GLU CYS PHE LEU GLN SEQRES 9 A 585 HIS LYS ASP ASP ASN PRO ASN LEU PRO ARG LEU VAL ARG SEQRES 10 A 585 PRO GLU VAL ASP VAL MET CYS THR ALA PHE HIS ASP ASN SEQRES 11 A 585 GLU GLU THR PHE LEU LYS LYS TYR LEU TYR GLU ILE ALA SEQRES 12 A 585 ARG ARG HIS PRO TYR PHE TYR ALA PRO GLU LEU LEU PHE SEQRES 13 A 585 PHE ALA LYS ARG TYR LYS ALA ALA PHE THR GLU CYS CYS SEQRES 14 A 585 GLN ALA ALA ASP LYS ALA ALA CYS LEU LEU PRO LYS LEU SEQRES 15 A 585 ASP GLU LEU ARG ASP GLU GLY LYS ALA SER SER ALA LYS SEQRES 16 A 585 GLN ARG LEU LYS CYS ALA SER LEU GLN LYS PHE GLY GLU SEQRES 17 A 585 ARG ALA PHE LYS ALA TRP ALA VAL ALA ARG LEU SER GLN SEQRES 18 A 585 ARG PHE PRO LYS ALA GLU PHE ALA GLU VAL SER LYS LEU SEQRES 19 A 585 VAL THR ASP LEU THR LYS VAL HIS THR GLU CYS CYS HIS SEQRES 20 A 585 GLY ASP LEU LEU GLU CYS ALA ASP ASP ARG ALA ASP LEU SEQRES 21 A 585 ALA LYS TYR ILE CYS GLU ASN GLN ASP SER ILE SER SER SEQRES 22 A 585 LYS LEU LYS GLU CYS CYS GLU LYS PRO LEU LEU GLU LYS SEQRES 23 A 585 SER HIS CYS ILE ALA GLU VAL GLU ASN ASP GLU MET PRO SEQRES 24 A 585 ALA ASP LEU PRO SER LEU ALA ALA ASP PHE VAL GLU SER SEQRES 25 A 585 LYS ASP VAL CYS LYS ASN TYR ALA GLU ALA LYS ASP VAL SEQRES 26 A 585 PHE LEU GLY MET PHE LEU TYR GLU TYR ALA ARG ARG HIS SEQRES 27 A 585 PRO ASP TYR SER VAL VAL LEU LEU LEU ARG LEU ALA LYS SEQRES 28 A 585 THR TYR GLU THR THR LEU GLU LYS CYS CYS ALA ALA ALA SEQRES 29 A 585 ASP PRO HIS GLU CYS TYR ALA LYS VAL PHE ASP GLU PHE SEQRES 30 A 585 LYS PRO LEU VAL GLU GLU PRO GLN ASN LEU ILE LYS GLN SEQRES 31 A 585 ASN CYS GLU LEU PHE GLU GLN LEU GLY GLU TYR LYS PHE SEQRES 32 A 585 GLN ASN ALA LEU LEU VAL ARG TYR THR LYS LYS VAL PRO SEQRES 33 A 585 GLN VAL SER THR PRO THR LEU VAL GLU VAL SER ARG ASN SEQRES 34 A 585 LEU GLY LYS VAL GLY SER LYS CYS CYS LYS HIS PRO GLU SEQRES 35 A 585 ALA LYS ARG MET PRO CYS ALA GLU ASP TYR LEU SER VAL SEQRES 36 A 585 VAL LEU ASN GLN LEU CYS VAL LEU HIS GLU LYS THR PRO SEQRES 37 A 585 VAL SER ASP ARG VAL THR LYS CYS CYS THR GLU SER LEU SEQRES 38 A 585 VAL ASN ARG ARG PRO CYS PHE SER ALA LEU GLU VAL ASP SEQRES 39 A 585 GLU THR TYR VAL PRO LYS GLU PHE ASN ALA GLU THR PHE SEQRES 40 A 585 THR PHE HIS ALA ASP ILE CYS THR LEU SER GLU LYS GLU SEQRES 41 A 585 ARG GLN ILE LYS LYS GLN THR ALA LEU VAL GLU LEU VAL SEQRES 42 A 585 LYS HIS LYS PRO LYS ALA THR LYS GLU GLN LEU LYS ALA SEQRES 43 A 585 VAL MET ASP ASP PHE ALA ALA PHE VAL GLU LYS CYS CYS SEQRES 44 A 585 LYS ALA ASP ASP LYS GLU THR CYS PHE ALA GLU GLU GLY SEQRES 45 A 585 LYS LYS LEU VAL ALA ALA SER GLN ALA ALA LEU GLY LEU HET MYR A 601 16 HET MYR A 602 16 HET MYR A 603 16 HET MYR A 604 16 HET EVP A 605 42 HETNAM MYR MYRISTIC ACID HETNAM EVP (5S,5AR,8AR,9R)-9-(4-HYDROXY-3,5-DIMETHOXYPHENYL)-8- HETNAM 2 EVP OXO-5,5A,6,8,8A,9-HEXAHYDROFURO[3',4':6,7]NAPHTHO[2,3- HETNAM 3 EVP D][1,3]DIOXOL-5-YL 4,6-O-[(1R)-ETHYLIDENE]-BETA-D- HETNAM 4 EVP GLUCOPYRANOSIDE HETSYN EVP ETOPOSIDE; VP-16 FORMUL 2 MYR 4(C14 H28 O2) FORMUL 6 EVP C29 H32 O13 FORMUL 7 HOH *68(H2 O) HELIX 1 1 SER A 5 GLY A 15 1 11 HELIX 2 2 GLY A 15 LEU A 31 1 17 HELIX 3 3 PRO A 35 ASP A 56 1 22 HELIX 4 4 SER A 65 CYS A 75 1 11 HELIX 5 5 LEU A 80 GLY A 85 1 6 HELIX 6 6 GLU A 86 LYS A 93 5 8 HELIX 7 7 GLN A 94 GLN A 104 1 11 HELIX 8 8 GLU A 119 ASN A 130 1 12 HELIX 9 9 ASN A 130 ARG A 144 1 15 HELIX 10 10 TYR A 150 CYS A 169 1 20 HELIX 11 11 ASP A 173 GLY A 207 1 35 HELIX 12 12 GLY A 207 PHE A 223 1 17 HELIX 13 13 GLU A 227 CYS A 246 1 20 HELIX 14 14 ASP A 249 ASN A 267 1 19 HELIX 15 15 GLN A 268 ILE A 271 5 4 HELIX 16 16 GLU A 277 LYS A 281 5 5 HELIX 17 17 PRO A 282 ALA A 291 1 10 HELIX 18 18 LEU A 305 VAL A 310 1 6 HELIX 19 19 ASP A 314 ALA A 322 1 9 HELIX 20 20 ALA A 322 HIS A 338 1 17 HELIX 21 21 SER A 342 CYS A 361 1 20 HELIX 22 22 ASP A 365 TYR A 370 1 6 HELIX 23 23 LYS A 372 ASP A 375 5 4 HELIX 24 24 GLU A 376 GLN A 397 1 22 HELIX 25 25 LEU A 398 VAL A 415 1 18 HELIX 26 26 SER A 419 CYS A 438 1 20 HELIX 27 27 LYS A 439 HIS A 440 5 2 HELIX 28 28 PRO A 441 ALA A 443 5 3 HELIX 29 29 LYS A 444 THR A 467 1 24 HELIX 30 30 SER A 470 GLU A 479 1 10 HELIX 31 31 ASN A 483 ALA A 490 1 8 HELIX 32 32 HIS A 510 THR A 515 5 6 HELIX 33 33 SER A 517 LYS A 536 1 20 HELIX 34 34 THR A 540 CYS A 559 1 20 HELIX 35 35 ASP A 563 LEU A 583 1 21 SSBOND 1 CYS A 53 CYS A 62 1555 1555 2.02 SSBOND 2 CYS A 75 CYS A 91 1555 1555 2.04 SSBOND 3 CYS A 90 CYS A 101 1555 1555 2.03 SSBOND 4 CYS A 124 CYS A 169 1555 1555 2.03 SSBOND 5 CYS A 168 CYS A 177 1555 1555 2.03 SSBOND 6 CYS A 200 CYS A 246 1555 1555 2.03 SSBOND 7 CYS A 245 CYS A 253 1555 1555 2.04 SSBOND 8 CYS A 265 CYS A 279 1555 1555 2.03 SSBOND 9 CYS A 278 CYS A 289 1555 1555 2.03 SSBOND 10 CYS A 316 CYS A 361 1555 1555 2.04 SSBOND 11 CYS A 360 CYS A 369 1555 1555 2.04 SSBOND 12 CYS A 392 CYS A 438 1555 1555 2.04 SSBOND 13 CYS A 437 CYS A 448 1555 1555 2.03 SSBOND 14 CYS A 461 CYS A 477 1555 1555 2.04 SSBOND 15 CYS A 476 CYS A 487 1555 1555 2.05 SSBOND 16 CYS A 514 CYS A 559 1555 1555 2.03 SSBOND 17 CYS A 558 CYS A 567 1555 1555 2.03 SITE 1 AC1 10 LEU A 22 VAL A 23 LEU A 66 PHE A 70 SITE 2 AC1 10 TYR A 150 ALA A 254 ARG A 257 LEU A 283 SITE 3 AC1 10 LEU A 284 SER A 287 SITE 1 AC2 6 SER A 342 VAL A 344 ARG A 348 LEU A 430 SITE 2 AC2 6 ARG A 485 MYR A 603 SITE 1 AC3 10 LEU A 387 ASN A 391 ARG A 410 TYR A 411 SITE 2 AC3 10 VAL A 415 LEU A 460 VAL A 473 PHE A 488 SITE 3 AC3 10 SER A 489 MYR A 602 SITE 1 AC4 5 TYR A 401 PHE A 507 LYS A 525 VAL A 547 SITE 2 AC4 5 PHE A 551 SITE 1 AC5 13 ASP A 108 HIS A 146 TYR A 148 SER A 193 SITE 2 AC5 13 ARG A 197 CYS A 200 ALA A 201 GLN A 204 SITE 3 AC5 13 CYS A 246 HIS A 247 GLY A 248 GLU A 280 SITE 4 AC5 13 HOH A 701 CRYST1 172.543 38.677 99.221 90.00 104.56 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.005796 0.000000 0.001506 0.00000 SCALE2 0.000000 0.025855 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010413 0.00000